Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-03-12

FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for KEPPRA XR (levetiracetam) from UCB, Inc., related to the extended-release formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEPPRA XR (levetiracetam)

Snippet

SUPPL AP for KEPPRA XR (LEVETIRACETAM)